A dual GIP / GLP-1 receptor agonist taken once a week.

Studied forFDA-approved for type 2 diabetes and chronic weight management. In the SURMOUNT-1 trial, adults with obesity lost substantially more weight than with placebo over 72 weeks.

An investigational triple agonist of the GIP, GLP-1 and glucagon receptors.

Studied forBeing studied by Eli Lilly for obesity and type 2 diabetes in phase 3 (TRIUMPH) trials. It is not FDA-approved; Lilly has said it plans to file for approval in 2027.

A growth hormone-releasing hormone (GHRH) analog.

Studied forFDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Also studied for visceral fat and liver fat.

A 16-amino-acid peptide encoded by mitochondrial DNA, discovered in 2015.

Studied forIn mice it improved insulin sensitivity and protected against diet-induced weight gain. Human data are mostly observational (blood levels), not treatment trials.

A copy of the first 29 amino acids of natural growth hormone-releasing hormone.

Studied forWas FDA-approved for growth hormone deficiency in children. The brand was discontinued for manufacturing reasons; in 2013 FDA determined it was not withdrawn for safety or effectiveness. Studied for adult GH decline.

A GHRH analog modified to resist breakdown; shorter-acting than the DAC version.

Studied forStudied to boost natural GH pulses. Published human trials used the long-acting DAC version, so evidence for the no-DAC form is limited.

A five-amino-acid ghrelin-receptor agonist.

Studied forDescribed in 1998 as the first selective GH secretagogue (little effect on cortisol or prolactin in animal studies). Tested in a human trial for post-surgery gut recovery.

A six-amino-acid ghrelin-receptor agonist and one of the most potent GHRPs.

Studied forStudied for GH release and for effects on the heart. The GH response can fade with continued use.

Combines both GH pathways in one vial.

Studied forThe rationale is that the two pathways work together. No published clinical studies have tested this blend itself.

A 15-amino-acid fragment of a protein found in stomach juice.

Studied forIn animal studies it improved healing of tendon, ligament, muscle, bone and gut injuries. A 2025 systematic review found 35 preclinical studies and just 1 clinical study; a small 2025 pilot looked at IV safety in people.

A synthetic fragment of thymosin beta-4, a protein involved in cell movement and repair.

Studied forStudied in animals for wound, muscle and tissue repair. The full thymosin beta-4 protein has reached early human trials for eye surface healing.

Combines the two repair peptides above.

Studied forCombined for overlapping repair pathways. No published clinical studies have tested this blend.

A three-amino-acid fragment of alpha-melanocyte-stimulating hormone.

Studied forReduced intestinal inflammation in mouse colitis models. The FDA has said it has identified no human exposure data.

A modified, longer-acting analog of insulin-like growth factor 1, used mainly in cell-culture research.

Studied forDesigned to resist the proteins that normally bind IGF-1, so it stays active longer. No human clinical trials; IGF-1 can lower blood sugar. It is prohibited in sport and has turned up in black-market products.

A modified fragment of the stress hormone ACTH, usually given as a nasal spray.

Studied forUsed in Russia after stroke and for cognitive conditions; lab studies show effects on nerve-growth factors. Western clinical evidence is limited.

A synthetic analog of tuftsin, an immune-system peptide.

Studied forDeveloped in Russia as an anti-anxiety peptide and studied in small trials of generalized anxiety.

A nine-amino-acid peptide first isolated in 1977 during deep sleep in rabbits.

Studied forStudied for sleep and stress, with inconsistent results. How it works is still unresolved.

A naturally occurring copper-binding tripeptide found in blood plasma; levels fall with age.

Studied forWidely used in topical skincare; studied for collagen production, skin firmness and wound healing. Evidence for injected forms is limited.

A three-peptide blend pairing the copper peptide with two repair peptides.

Studied forCombines skin- and repair-focused compounds. No published studies have tested the blend itself.

GLOW plus KPV.

Studied forAdds KPV for its anti-inflammatory research profile. No published studies have tested the blend itself.

A four-amino-acid peptide that targets cardiolipin in the inner mitochondrial membrane.

Studied forIn September 2025 the FDA granted accelerated approval for Barth syndrome, a rare mitochondrial disease. Also studied in mitochondrial myopathy and heart failure.

A coenzyme found in every cell, essential to energy metabolism and DNA repair.

Studied forNAD+ levels decline with age. Human trials (mostly oral precursors such as NR and NMN) show NAD+ levels can be raised safely, but clinical benefits are still mixed.

A melanocortin-receptor agonist that acts in the brain rather than on blood flow.

Studied forFDA-approved in 2019 for acquired, generalized hypoactive sexual desire disorder (low sexual desire) in premenopausal women.

A natural nine-amino-acid hormone often called the 'bonding hormone'.

Studied forFDA-approved in hospitals to start or strengthen labor and control bleeding after birth. Nasal oxytocin has been studied for social connection and bonding, with mixed results.